KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

Heinz Ludwig, Evangelos Terpos, Mario Boccadoro, Sara Martínez, Carmen Kahatt, Javier Jiménez, Antonio Nieto, Sonia Extremera, Javier Gómez, Vicente Alfaro, Ruthanna Davi, Xiang Yin, María Victoria Mateos

Ann Hematol 105(1) 26

PMID41545603
PMCIDPMC12811270
DOI10.1007/s00277-026-06811-w
发表日期2026-01-16
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图。
摘要

摘要

Plitidepsin (P) is a marine-derived anticancer compound isolated from the tunicate Aplidium albicans. P plus low-dose dexamethasone (LD-DXM) was evaluated versus LD-DXM alone in patients with relapsed/refractory multiple myeloma (r/r MM) in the randomized phase III ADMYRE trial. In absence of a randomized study with P + LD-DXM vs. POM + LD-DXM, a direct matched comparison between P + LD-DXM (ADMYRE data) and pomalidomide (POM) + LD-DXM as an External Control Arm (ECA) was conducted using individual patient-level data from several contemporary POM + LD-DXM trials with a similar design. A first analysis (ECA1) showed that P + LD-DXM was non-inferior to POM + LD-DXM in terms of median overall survival (OS): 11.8 vs. 13.9 months; HR = 1.009 (95%CI, 0.812–1.254; p = 0.9336). Safety profile showed a lower rate of grade ≥ 3 hematological treatment-related adverse events (TRAEs) (neutropenia 2.5% vs. 37.1%; thrombocytopenia 2.5% vs. 13.2%) and infections (8.1% vs. 18.7%) for P + LD-DXM, and a higher rate of grade ≥ 1 gastrointestinal TRAEs (52.8% vs. 27.4%), grade ≥ 3 blood creatine phosphokinase (14.3% vs. 0%) and grade ≥ 3 myalgia (5.6% vs. 0%). A second analysis (ECA2) compared POM + LD-DXM with the LD-DXM alone arm included in ADMYRE and showed a treatment effect in OS (HR = 0.762; 95%CI, 0.566–1.026) similar to that observed in ADMYRE (HR = 0.797, 95%CI, 0.596–1.067). Safety profile of POM + LD-DXM was associated to a higher rate of TRAEs, as expected for a combination. In conclusion, P + LD-DXM can be an alternative therapeutic option in r/r MM as this comparison shows that P + LD-DXM is non-inferior in OS to POM + LD-DXM with an advantageous safety profile in terms of hematological and infection events.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Design of comparative analysis using external control arms. Abbreviations: LD-DXM, low-dose dexamethasone; ECA, external control arm; P, plitidepsin; POM, pomalidomide
非 KM Figure
Fig. 2Kaplan-Meier curve of overall survival (ECA1 analysis): P + LD-DXM (ADMYRE) vs. POM + LD-DXM arm. Includes the patients from both ADMYRE P + LD-DXM arm and ECA eligible pool who are matched for the baseline covariates. ‘+’ indicates censoring. The hazard ratio (95%CI) is based on the Cox proportional hazards regression model with treatment group (P + LD-DXM vs. POM + LD-DXM) as a single covariate. Abbreviations: C, censored; CI, confidence interval; ECA, external control arm; HCT, historical clinical trial; HR, hazard ratio; KM, Kaplan-Meier; OS, overall survival; P + LD-DXM, plitidepsin plus low-dose dexamethasone; POM + LD-DXM, pomalidomide plus low-dose dexamethasone
非 KM Figure
Fig. 3Kaplan-Meier curve of overall survival (ECA2 analysis): POM + LD-DXM vs. LD-DXM (ADMYRE). Includes the patients from both ADMYRE LD-DXM arm and ECA eligible pool who are matched for the baseline covariates. The hazard ratio (95%CI) is based on the Cox proportional hazards regression model with treatment group (POM + LD-DXM vs. LD-DXM) as a single covariate. Abbreviations: C, censored; CI, confidence interval; LD-DXM, low-dose dexamethasone; ECA, external control arm; HCT, historical clinical trial; HR, hazard ratio; KM, Kaplan-Meier; OS, overall survival; POM, pomalidomide
非 KM Figure